• Devon S Callahan, Angela Neville, Scott Bricker, Dennis Kim, Brant Putnam, Frederic Bongard, and David S Plurad.
• Department of Surgery, Division of Trauma/Acute Care Surgery and Surgical Critical Care, Harbor-UCLA Medical Center, Torrance, California. Electronic address: devon.callahan.md@gmail.com.
• J. Surg. Res. 2014 Jan 1;186(1):452-7.

BackgroundHormone replacement therapy (HRT) is becoming more common when managing brain-dead donors. Arginine vasopressin (AVP) is associated with benefits but is not consistently used. We hypothesize that AVP is associated with the maintenance of lung function and successful recovery in donors and enhanced lung graft performance in recipients.MethodsThe Organ Procurement and Transplantation Network database was used. Study donors were those treated with HRT and procured from January 1, 2009 to June 30, 2011. AVP (+) and AVP (-) donors were compared. Donor lung function, the rate of successful lung procurement, and the incidence of graft failure in recipients were studied.ResultsThere were 12,322 donors included, of which 7686 received AVP (62.4%). Cerebrovascular accident (4722 [38.3%]) was the most common cause of donor death. There was a significant increase in high yield (≥4 organs) (51.0% versus 39.3%, <0.001), mean number of organs (3.75 versus 3.33, <0.001), and rate of successful lung recovery (26.3% versus 20.5%, <0.001) with AVP. Lung function was preserved to a greater degree in donors receiving AVP. Adjusting the significant factors, AVP was independently associated with lung procurement (1.220 [1.114-1.336], <0.001). The incidence of early graft failure was not changed.ConclusionsAVP with HRT is associated with the maintenance of lung function and a significant increase in successful organ recovery in donors without untoward effects in the recipient. AVP should be universally adopted as a component of HRT in the management of donors with neurologic death.Copyright © 2014 Elsevier Inc. All rights reserved.

16 keywords...

hide…